» Articles » PMID: 25784996

ABCB1 (rs1128503) Polymorphism and Response to Chemotherapy in Patients with Malignant Tumors-evidences from a Meta-analysis

Overview
Specialty General Medicine
Date 2015 Mar 19
PMID 25784996
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Numerous papers have reported ABCB1 polymorphisms are associated with the response to chemotherapy of cancers. The inconclusive results call for a comprehensive analysis, for the sample size of the published studies is comparatively small. Therefore, a comprehensive meta-analysis was performed on the basis of the published studies for an accurate estimation of such association. Altogether 8 comparative studies including 2463 cancer patients were involved in our meta-analyses. ABCB1 C1236T (rs1128503) polymorphism was shown to be associated with tumor response to chemotherapy in cancer patients under the dominant model (OR=1.72, 95% CI=1.09-2.73, P=0.177, I(2)=36.60%) and additive model (OR=1.99, 95% CI=1.39-2.85, P=0.222, I(2)=25.90%). A subgroup meta-analysis indicated a significant association under dominant model between ABCB1 C1236T (rs1128503) polymorphism and breast cancer in the Asians (OR=2.15, 95% CI=1.22-3.77, P=0.210, I(2)=33.70%). These results suggest that ABCB1 C1236T (rs1128503) might contribute to the tumor response to chemotherapy in cancers from the Asians, especially in the osteosarcoma and breast cancer.

Citing Articles

Efficacy and safety of Trastuzumab Emtansine in treating human epidermal growth factor receptor 2-positive metastatic breast cancer in Chinese population: a real-world multicenter study.

He M, Zhao W, Wang P, Li W, Chen H, Yuan Z Front Med (Lausanne). 2024; 11:1383279.

PMID: 38741766 PMC: 11089149. DOI: 10.3389/fmed.2024.1383279.


Pharmacogenomics and Morphine.

Ofoegbu A, Ettienne E J Clin Pharmacol. 2021; 61(9):1149-1155.

PMID: 33847389 PMC: 8453761. DOI: 10.1002/jcph.1873.


Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis.

Chen Q, Lin W, Yang J, Lin M, Lin X, Weng Y Asian Pac J Cancer Prev. 2021; 22(1):3-10.

PMID: 33507672 PMC: 8184199. DOI: 10.31557/APJCP.2021.22.1.3.


Genetic Polymorphisms in Multispecific Transporters Mitigate Mercury Nephrotoxicity in an Artisanal and Small-Scale Gold Mining Community in Colombia.

Sanchez Rodriguez L, Medina Perez O, Rondon Gonzalez F, Rincon Cruz G, Rocha Munoz L, Florez-Vargas O Toxicol Sci. 2020; 178(2):338-346.

PMID: 32946573 PMC: 7825076. DOI: 10.1093/toxsci/kfaa142.


Association between polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer.

Al-Ghafari A, Al Qahtani A, Alturki S, Al Doghaither H, Elmorsy E, Tashkandi H Oncol Lett. 2020; 20(5):155.

PMID: 32934723 PMC: 7471754. DOI: 10.3892/ol.2020.12016.


References
1.
Yang J, Wang Z, Cai H, Li Y, Xu Y . Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Asian Pac J Cancer Prev. 2013; 14(8):4595-8. DOI: 10.7314/apjcp.2013.14.8.4595. View

2.
Pan J, Han J, Wu J, Sheng L, Huang H, Yu Q . MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration. 2007; 75(4):380-5. DOI: 10.1159/000108407. View

3.
Wei H, Lu X, Shang L, Xu G, Hu J, Che D . Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res. 2011; 42(5):412-20. DOI: 10.1016/j.arcmed.2011.07.008. View

4.
Wu H, Kang H, Liu Y, Tong W, Liu D, Yang X . Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol. 2012; 138(9):1449-62. DOI: 10.1007/s00432-012-1209-z. View

5.
Li J, Tian Z, Jiang S, Feng T . Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy. Genet Mol Res. 2014; 13(2):3186-92. DOI: 10.4238/2014.April.25.3. View